Logo

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

Jan 13, 2021

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine. 

Breaking News
The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.